Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: A study of the Eastern Cooperative Oncology Group (E5Y92)

Journal of Immunotherapy

Volumn 33, Issue 9, 2010, Pages 1006-1009

  Wiernik, Peter H ^a,b   Dutcher, Janice P ^a,b   Yao, Xiapan ^b,c   Venkatraj, Usha ^a,b   Falkson, Carla I ^b,d   Rowe, Jacob M ^b,f   Cassileth, Peter A ^b,e  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Eastern Cooperative Group   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f RAMBAM MEDICAL CENTER   (Israel)

Author keywords

chronic lymphocytic leukemia; interleukin 4; interleukin 6; low grade lymphoma

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; BILIRUBIN; CIMETIDINE; CREATININE; DIPHENHYDRAMINE; HYDROXYZINE; INTERLEUKIN 6; PARACETAMOL; RECOMBINANT INTERLEUKIN 4;

ADULT; ALLERGY; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL LYMPHOMA; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD LEVEL; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; GRANULOCYTOPENIA; HEART DISEASE; HUMAN; HYPERTENSION; INDOLENT B CELL NON HODGKIN LYMPHOMA; INFECTION; INJECTION SITE; LEUKEMIA; LEUKOCYTE COUNT; LIVER DISEASE; MALE; MENTAL DISEASE; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DISEASE; STOMATITIS; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT DISEASE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-4; INTERLEUKIN-6; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78149281980     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181f5dfc5     Document Type: Article

References (20)

1. Luo H, Rubio M, Biron G, et al. Antiproliferative effects of IL-4 in B chronic lymphocytic leukemia. J Immunother. 1991;10:418-425.
2. Lee D, Swisher SG, Minehart EH, et al. Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells. J Leukocyte Biol. 1990;47:475-479.
3. Te Vede M, Huijbens RJF, Heije K, et al. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood. 1990;76:1392-1397.
4. Trehu EG, Isner JM, Mier JW, et al. Possible myocardial toxicity associated with interleukin-4 therapy. J Immunother Emphasis Tumor Immunol. 1993;348-351.
5. Freimann J, Estrov Z, Itoh K, et al. Phase I studies of recombinant human IL-4 in patients with hematologic malignancies. Blood. 1990;76(suppl): 93. (Abstract 361a)
6. Maher D, Boyd A, McKendrick J, et al. Rapid response of B-cell malignancies induced by IL-4. Blood. 1990;76(suppl): 152. (Abstract 600a)
7. Maher DW, Davis I, Boyd AW, et al. Human IL-4: an immunomodulator with potential therapeutic applications. Progress Growth Factor Res. 1991;3:43-56.
8. Davis I, Maher D, Cebon J, et al. Pharmacokinetic and clinical studies of IL-4 in patients with malignancy. Proc Am Soc Clin Oncol. 1991;10:287. (Abstract 1006a)
9. Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics. 1985;41:741-744.
10. Dutcher JP, Venkatraj U, Makower D, et al. Interleukin-4 is a pleotropic cytokine with effects on B-cell malignancies. Leukemia Res. 1997;21:17-19.
11. Oleksowicz L, Dutcher JP. A review of the new cytokines: IL4, IL6, IL11 and IL12. Am J Ther. 1994;1:107-115.
12. Costello R, Lipcey C, Olive D. Rationale for the utilization of interleukin-4, an immune-recognition induced cytokine, in cancer immunotherapy. Eur J Med. 1993;2:54-57.
13. Gilleece MH, Scarffe JH, Ghosh A, et al. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections- a phase I dose toxicity trial. Br J Cancer. 1992;204-210.
14. Leach MW, Rybak ME, Rosenblum IY. Safety evaluation of recombinant human interleukin-4. II. Clinical studies. Clin Immunol Immunopathol. 1997;83:12-14.
15. Taylor CW, LeBlanc M, Fisher RI, et al. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. Anticancer Drugs. 2000;11:695-700.
16. Prendiville J, Thatcher N, Lind M, et al. Recombinant human interleukin-4 (rhuIL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer-a phase I toxicity study and pharmacokinetic analysis. Eur J Cancer. 1993;29 A: 1700-1707.
17. Makower D, Venkatraj U, Dutcher JP, et al. Occurrence of myeloma in a chronic lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leukemia Lymphoma. 1996;23:617-619.
18. Lundin J, Kimby E, Bergmann L, et al. Interleukin 4 therapy for patients with chronic lymphocytic leukemia: a phase I/II study. Br J Haematol. 2001;112:155-160.
19. Kurtz DM, Tschetter LK, Alfred JB, et al. Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leukemia Lymphoma. 2007;48:1290-1298.
20. Martin H, Leonard JM. IL-4 therapy for non-Hodgkin's lymphoma: possibilities but major challenges. Leukemia Lymphoma. 2007;48:1259-1260.